A Double-Blind, Placebo-Controlled, Multicenter Study of Sirukumab as Adjunctive Treatment to a MonoAminergic Antidepressant in Adults with Major Depressive Disorder

ID Number 15-1210

Principal Investigator(s)
James Murrough

Department(s) or Division(s)

Research Entity
Mood and Anxiety Disorders Program - MAP


The purpose of this study is to evaluate the efficacy of sirukumab as an adjunctive treatment to antidepressant therapy (monoaminergic antidepressant). Sirukumab will be administered as a subcutaneous injection three times during the 12-week double blind treatment period.

Contact Information
Marin Kautz
(212) 241-7906

Recruiting Patients: Yes